Nevertheless, evidence was provided about the therapeutic benefit of the combinatorial use of trastuzumab and the HDAC6 inhibitor NextA in HER2+ BC patients, including those undergoing trastuzumab resistance. Here, ERBB2 is linked to breast cancer.